Chemotherapy and management of tuberculosis in the United Kingdom: Recommendations 1998

Thorax

Volumn 53, Issue 7, 1998, Pages 536-548

  Ormerod, Peter ^a   Campbell, Ian ^b   Novelli, Vas ^c   Pozniak, Anton ^d   Davies, Peter ^e   Skinner, Craig ^f   Moorc Gillon, John ^g   Darbyshire, Janet ^h   Drobniewski, Francis ⁱ  

^a ROYAL BLACKBURN HOSPITAL   (United Kingdom)

^b LLANDOUGH HOSPITAL   (United Kingdom)

^c GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^d KING S COLLEGE HOSPITAL   (United Kingdom)

^e UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^f BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^g ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^h MEDICAL RESEARCH COUNCIL   (United Kingdom)

ⁱ PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

BTS guidelines; Tuberculosis

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AZITHROMYCIN; BCG VACCINE; CAPREOMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; DIAZEPAM; DIGITOXIN; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; ISONIAZID PLUS RIFAMPICIN; KANAMYCIN; METHADONE; OFLOXACIN; PHENYTOIN; PREDNISOLONE; PROBENECID; PROTIONAMIDE; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; RIFATER; STREPTOMYCIN; THIOACETAZONE; TUBERCULIN; TUBERCULOSTATIC AGENT; UNINDEXED DRUG; WARFARIN;

ACUTE KIDNEY FAILURE; ARTHRALGIA; BLOOD TOXICITY; CHEMOPROPHYLAXIS; DEPRESSION; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NEUROTOXICITY; OTOTOXICITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SKIN ALLERGY; TUBERCULIN TEST; TUBERCULOSIS; UNITED KINGDOM; UVEITIS;

EID: 0010381075     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.53.7.536     Document Type: Review

References (110)

1. Watson JM, Fern KJ, Porter JDH, et al. Notification of tuberculosis in England and Wales 1982-9. Comm Dis Report 1990;1:R13-15.
2. Hayward AC, Watson JM. Tuberculosis in England and Wales 1982-93: notifications exceeded predictions. Comm Dis Report 1995;5:R29-33.
3. Hayward AC, Bennett DE, Herbert J, et al. Risk factors for drug resistance in patients with tuberculosis in England and Wales 1993-94. Thorax 1996;51(Suppl 3):S32.
4. Kumar D, Watson JM, Charlett A, et al. Tuberculosis in England and Wales in 1993: results of a national survey. Thorax 1997; 52: 1060-7.
5. Joint Tuberculosis Committee of the British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations of the Joint Tuberculosis Commitee of the British Thoracic Society. Thorax 1990;45:403-8.
6. Subcommittee of the Joint Tuberculosis Committee. Guidelines on the management of tuberculosis and HIV infecton in the United Kingdom. BMJ 1992;304:1231-3.
7. Ormerod LP, Bentley C for the Joint Tuberculosis Committee of the British Thoracic Society. The management of pulmonary tuberculosis in England and Wales in 1993. J Roy Coll Phys Lond 1997; 31: 662-5.
8. Ormerod LP, Bentley C for the Joint Tuberculosis Committee of the British Thoracic Society. Management of lymph node tuberculosis in England and Wales in 1993. J Roy Coll Phys Lond 1997;31: 666-8.
9. Girling DJ. The chemotherapy of tuberculosis. In: Ratle C, Stanford J, Grange JM, eds. Biology of mycobacteria - clinical aspects of mycobacteria. Vol 3. London: Academic Press, 1989:285-323.
10. Mitchison DA. Treatment of tuberculosis. J R Coll Phys 1980;14:91-9.
11. Jindani A, Aber VR, Edwards EA, et al. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 1980;121:139-48.
12. Anonymous. Chemotherapy of pulmonary tuberculosis in Britain. Drug Ther Bull 1988;26:1-4.
13. British Thoracic Association. A controlled trial of 6-months chemotherapy in pulmonary tuberculosis. First report: results during chemotherapy. Br J Dis Chest 1981:75:141-153.
14. Singapore Tuberculosis Service and British Medical Research Council. Clinical trial of six-month and four-month chemotherapy in the treatment of pulmonary tuberculosis. The results up to 30 months. Tubercle 1981;62:95-102.
15. East and Central African and British Medical Research Council. Clinical controlled trial of four short-course regimens of chemotherapy (three six-month, and one eight-month) for pulmonary tuberculosis. Tubercle 1983:64:153-66.
16. British Thoracic Society. A controlled trial of six-months chemotherapy in pulmonary tuberculosis. Final report: results during the 36 months after the end of chemotherapy and beyond. Br J Dis Chest 1984:78:330-6.
17. Singapore Tuberculosis Service and British Medical Research Council. Clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 1985;132:374-8.
18. Snider DE, Graczyk DE, Bek E, et al. Supervised six-months treatment of newly diagnosed pulmonary tuberculosis using isoniazid, rifampin and pyrazinamide with or without streptomycin. Am Rev Respir Dis 1984;130:1091-4.
19. Prabhakar R. Fully intermittent six-month regimens for pulmonary tuberculosis in South India. In: Proceedings of the XXVI World IUAT Conference, Singapore. Professional Postgraduate Services, Japan, 1987:21-3.
20. British Thoracic Society Research Committee. Six months versus nine months chemotherapy for tuberculosis of lymph nodes:preliminary results. Respir Med 1992;86:15-9.
21. Campbell IA, Ormerod LP, Friend JAR, et al. Six months versus nine months chemotherapy for tuberculosis of lymph nodes:final results. Respir Med 1993;87. 621-3.
22. Campbell IA, Dyson AJ. Lymph node tuberculosis:a comparison of various methods of treatment. Tubercle 1977;58: 171-9.
23. Campbell IA, Dyson AJ. Lymph node tuberculosis:a comparison of treatments 18 months after completion of chemotherapy. Tubercle 1979;60:95-8.
24. Girling DJ, Darbyshire JH, Humphries MJ, et al. Extra-pulmonary tuberculosis. Br Med Bull 1988;44:738-56.
25. Medical Research Council Working Party on Tuberculosis of the Spine. A controlled trial of 6-month and 9-month regimens of chemotherapy in patients undergoing radical surgery for tuberculosis of the spine in Hong Kong. Tubercle 1986;67:243-59.
26. Medical Research Council Working Party on Tuberculosis of the Spine. Controlled trial of short-course regimens of chemotherapy in ambulatory treatment of spinal tuberculosis. J Bone Joint Surg 1993;75:240-8.
27. Indian Council of Medical Research/British Medical Research Council Working Party. A controlled trial of short-course regimens of chemotherapy in patients receiving ambulatory treatment or undergoing radical surgery for tuberculosis of the spine, Ind J Tuberc 1989;36(Suppl): 1-22.
28. Strang JIG, Kakaka HHS, Gibson DG, et al. Controlled trial of prednisolone as an adjuvant in treatment of tuberculous constrictive pericarditis in Transkei. Lancet 1987;ii: 1418-22.
29. Strang JIG, Kakaka HHS, Gibson DG, et al. Controlled clinical trial of complete open surgical drainage and of prednisolone in treatment of tuberculous pericardial effusion in Transkei. Lancet 1988;ii:759-63.
30. Ellard GA, Humphries MJ, Gabriel M, et al. Penetration of pyrazinamide into the CSF in tuberculous meningitis. BMJ 1985;294:284-5.
31. Humphries M. The management of tuberculous meningitis. Thorax 1992;47:577-81.
32. Donald PR, Seifart HI. Cerebrospinal fluid concentrations of ethionamide in children with tuberculous meningitis. J. Pediatr 1989;115:383-6.
33. Citron KM, Thomas GO. Ocular toxicity from ethambutol. Thorax 1986;41:737-9.
34. Ormerod LP, Watson JM, Pozniak A, et al. Notification of tuberculosis: an updated code of practice for England and Wales. J R Coll Phys 1997:31:299-303.
35. American Academy of Pediatrics. Tuberculosis. In: Peter G, ed. 1994 Red Book Report of the Committee on Infectious Diseases. 23rd edn. Elk Grove Village, IL. American Academy of Pediatrics, 1994: 480-500.
36. American Academy of Pediatrics, Committee on Infectious Diseases. Chemotherapy for tuberculosis in infants and children. Pediatrics 1992;89:161-5.
37. International Union against Tuberculosis and Lung Disease. Antituberculosis regimens of chemotherapy. Recommendation from the committee on treatment of IUATLD. Bull Im Union Tuberc Lung Dis 1988;63:60-4.
38. World Health Organisation Tuberculosis Unit. Division of Communicable Diseases. Guidelines for tuberculosis treatment in adults and children in national treatment programmes. WHO Geneva, 1991: WHO/tuberculosis 91:1-61.
39. Grange JM. Antimycobacterial agents. In: O'Grady F, Lambert HP, Finch RG, Greenwood D, eds. Antibiotics and chemotherapy. 7th edn. Churchill Livingstone, 1997: 499-512.
40. American Thoracic Society. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994;149:1359-74.
41. Jacobs RF, Eisenach KD. Childhood tuberculosis. Adv Pediatr Infect Dis 1993;8:23-51.
42. Inselman L. Tuberculosis in children: an update. Pediatr Pulmonol 1996;21:101-20.
43. Roy V, Tekur U, Chopra K. Pharmacokinetics of isoniazid in pulmonary tuberculosis: a comparative study at two dose levels. Indian Pediatr 1996;33:287-91.
44. Mazouni SM. Short-course chemotherapy (6 months) for respiratory tuberculosis in children: results at 30 months. Bull Int Union Tuberc 1986;61:16-17.
45. Palma Beltran OR, Pelosi F, Budani H, et al. The treatment of child tuberculosis with isoniazid (H), rifampicin (H) and pyrazinamide (Z). Bull Int Union Tuberc 1986;61:17.
46. Trebucq A. Should ethambutol be recommended for routine treatment of tuberculosis in children? A review of the literature. Int J Tuberc Lung Dis 1997;1:12-15.
47. Hendy M, Stableforth D.E. The effect of established diabetes mellitus on the presentation of infiltrative pulmonary tuberculosis in the immigrant asian community of an inner city area of the United Kingdom. Br J Dis Chest 1983;77:87-9.
48. Ormerod LP, Skinner C, Wales JM. Hepatotoxicity of antituberculosis drugs. Thorax 1996;51:111-3.
49. Anonymous. Tuberculosis in patients having dialysis (editorial). BAJ 1980;1:349.
50. Edwards OM, Courtney-Evans RJ, Galley JM, et al. Changes in Cortisol metabolism following rifampicin therapy. Lancet 1974,ii:549-51.
51. Schoerman JF, Van Zyl LE, Laubscher JA, et al. Effects of corticosteroids on intracranial pressure, computed tomo-graphic findings, and clinical outcome in young children with tuberculous meningitis. Pediatrics 1997;99:226 31.
52. Toppet M, Malfroot A, Derde MP, et al. Corticosteroids in primary tuberculosis with bronchial obstruction Arch Dis Child 1990;65:1222-6.
53. Horne NW, Tulloch WS. Conservative management of renal tuberculosis. Br J Urol 1975;47:481-7.
54. Lee CH. Wang WJ, Lan RS, et al. Corticosteroids in the treatment of tuberculous pleurisy. A double blind, placebo controlled, randomized study. Chest 1988;94:1256-9.
55. Horne NW. A critical evaluation of corticosteroids in tuberculosis. Adv Tubcrc Res 1966;15:1-54.
56. Grosset JH. Treatment of tuberculosis in HIV infection. Tuberc Lung Dis 1992;73:378-83.
57. Ackah AN, Coulibaly D, Digbeu H, et al. Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Cote d'Ivoire. Lancet 1995;345:607-10.
58. Perriens JH, St.Louis ME, Yiadiul B, et al. Pulmonary tuberculosis in HIV-infected patients in Zaire. N Engl Med J 1995;332:779-84.
59. Joint Tuberculosis Committee of the British Thoracic Society. Control and prevention of tuberculosis in the United Kingdom: code of practice 1994. Thorax 1994;49: 1193-200.
60. Interdepartmental Working Group on Tuberculosis. United Kingdom recommendations for the prevention and control of HIV-related tuberculosis and drug-resistant, including multiple drug-resistant, tuberculosis. Consultation document. London: Department of Health, 1997.
61. Small PM, Schecter GF, Goodman PC, et al. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. N Engl J Med 1990:324:289-94.
62. Morse DI. Directly observed therapy for tuberculosis. BMJ 1996;312:719-20.
63. China Tuberculosis Control Collaboration. Results of directly observed short-course chemotherapy in 112,842 Chinese patients with smear-positive tuberculosis. Lancet 1996;347:358-62.
64. Caminero JA, Pavon JM, Rodriguez de Castro F, et al. Evaluation of a directly observed six month fully intermittent treatment regimen for tuberculosis in patients suspected of poor compliance. Thorax 1996;51:1130-3.
65. Centers for Disease Control. Initial therapy for tuberculosis in the era of multidrug resistance: recommendations of the advisory council for the elimination of tuberculosis. MMWR Morb Mortal Wkly Rep 1993;42:RR-7.
66. Moore RD, Chaulk CP, Griffiths R, et al. Cost-effectiveness of directly observed versus self administered therapy for tuberculosis. Am J Respir Crit Care Med 1996; 154:1013-9.
67. Sbarbaro JA. The ultimate decision analysis:the confirmation of reality through theory. Am J Respir Crit Care Med 1996;154:835-6.
68. Miller B, Palmer CS, Halpern MT, et al. Decision model to assess the cost-effectiveness of DOT for tuberculosis. Tuberc Lung Dis 1996;77(Suppl 2):74-5.
69. Sumartojo E. When tuberculosis treatment fails:a social behavioural account of patient adherence. Am Rev Respir Dis 1993;147:1311-20.
70. Schluger N, Ciotoli C, Cohen D, et al. Comprehensive tuberculosis control for patients at high risk for noncompliance. Am J Respir Crit Care Med 1995;151:1486-90.
71. Rolfe LM, Millard FJC, Rayner CFJ. A programme of directly observed therapy for tuberculosis in London. Thorax 1996;51(Suppl 3):A32.
72. Sell L, Finch E, Farrell M, et al. Directly observed treatment for tuberculosis. BMJ 1996;313:45.
73. Raistrick D, Hay A, Wolff K. Methadone maintainance and tuberculosis treatment. BMJ 1996;313 925-6.
74. Chowdhury AMR, Chowdury S, Islam MN, et al. Control of tuberculosis by community health workers in Bangladesh. Lancet 1997;350:169-72.
75. Englehard D, Stutman HR, Marks MI. Interaction of ketoconazole with rifampicin and isoniazid. N Engl Med J 1994;311:1681-3.
76. Lazar JD, Wilner KD. Drug interactions with fluconazole. Rev Infect Dis 1990;12(Suppl 3):S327-333.
77. Heyden R, Miller R. Adverse effects and drug interactions of medications commonly used in the treatment of adult HIV positive patients. Genitourinary Med 1996;72;237-46.
78. Heyden R, Miller R. Adverse effects and drug interactions of medications commonly used in the treatment of adult HIV positive patients: Part 2. Geniturinary Med 1997;73:5-11
79. Anonymous. Clinical update. Impact of HIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampicin. MMWR 1996;45:921-5.
80. McGregor MM, Olliaro P, Wolramans L, et al. Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis. Am J Respir Crit Care Med 1996;154:1462-7.
81. Bass JB, Farer LS, Hopewell PC, et al. Treatment of tuberculosis and tuberculosis infection in adults and children. Clin Infect Dis 1995;21:9-27.
82. Davies PDO, Girling DJ, Grange JM. Tuberculosis. In: Weatherall DJ, Ledingham JGG, Orrell DJ, eds.Oxford textbook of medicine. 3rd edn. Oxford: Oxford Medical Publications, 1995: 638-661.
83. Horne NW Modern drug treatment of tuberculosis. 7th edn. London: Chest Heart and Stroke Association, 1990: 32 5.
84. Ellard GA, Ellard DR, Allen BW, et al. The bioavailability of isoniazid, rifampin and pyrazinamide in two comercially available combined formulations designed for use in short-course therapy in tuberculosis. Am Rev Respir Dis 1986:133:1076-80.
85. Geiter LJ, O'Brien RJ, Coombs DL, et al. United States Public Health Service tuberculosis therapy trial 21. Preliminary results of an evaluation of a combination tablet of isoniazid, rifampin and pyrazinamide. Tubercle 1987; 68:41-6.
86. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. A general review. Adv Tuberc Res 1970;17:28-104.
87. Thomson NJ. Efficacy of various durations of isoniazid preventive therapy in tuberculosis: 5 years of follow-up in the IUAT trial. Bull WHO 1982;60:555-64.
88. Ormerod LP. Rifampicin and isoniazid prophylaxis for tuberculosis. Arch Dis Child 1998;78: 169-71.
89. Hong Kong Chest Service/Tuberculosis Research Centre Madras/ British Medical Research Council. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis 1992;145:36-41
90. Polesky A, Forber HW, Gotlieb DJ, et al. Rifampin preventive therapy for tuberculosis in Boston's homeless. Am J Respir Crit Care Med 1996;154:1473 7.
91. Departments of Health. Immunisation against infectious disease. London: HMSO, 1996: 232.
92. Outbreak Forum IV. High prevalence of tuberculin sensitivity. Commun Dis Rep 1992;1:R67-9.
93. IUATLD, GPA (WHO). Tuberculosis preventive therapy in HIV infected individuals; a joint statement of the IUATLD and GPA (WHO). Tuberc Lung Dis 1994;75:96 8.
94. Fitzgerald JM. The downside of isoniazid chemoprophylaxis. Lancet 1995;345:404.
95. Aisu T, Raviglione MC, Van Praag E, et al. Preventive chemotherapy for HIV associated tuberculosis in Uganda: an operational assessment of a voluntary counselling and testing centre. AIDS 1995;9:267-73.
96. Gordin FM, Matts JP, Miller C, et al. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. N Engl J Med 1997;337:315-20.
97. Neville K, Bromberg A, Bromberg R, et al. The third epidemic: multidrug resistant tuberculosis. Chest 1994; 105:45-8.
98. Rouillon A, Predizet S, Parrot R. Transmission of tubercle bacilli. The effects of chemotherapy. Tubercle 1976;57:275 99.
99. Babu Swai O, Alnoch JA, Githui WA, et al. Controlled clinical trial of a regimen of two durations for the treatment of isoniazid resistant tuberculosis. Tubercle 1988;69:5-14.
100. Mitchison DA, Nunn AJ. Influence of initial drug resistance on the response to short-course chemotherapy in pulmonary tuberculosis. Am Rev Respir Dis 1986;133: 423-30.
101. Telenti A, Imboden P, Marchesi F, et al. Detection of rifampicin-resistance mutation in Mycobacterium tuberculosis. Lancet 1993,341:647-50.
102. Drobniewski FA, Kent RJ, Stoker NG, et al. Molecular biology in the diagnosis and epidemiology of tuberculosis. J Hosp Infect 1994;28:249-63.
103. Drobniewski FA, Pozniak AL. Molecular diagnosis, detection of drug resistance and epidemiology of tuberculosis. Br J Hosp Med 1996;56:204-8.
104. Goyal M, Shaw RJ, Banerjee DK, et al. Rapid detection of multidrug-resitant tuberculosis. Eur Respir J 1997;10:120-4.
105. Drobniewski FA. Is death inevitable with multiresistant tuberculosis plus HIV infection? Lancet 1997;349:71-2.
106. Goble M, Iseman M, Madsen LA, et al. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993;328:527-32.
107. Iseman M. Treatment of multidrug-resistant tuberculosis. N Engl J Med 1993;329:784-90.
108. Gallagher CT, Passannante MR, Reichman LB. Preventive therapy for multidrug resistant tuberculosis (MDR-tuberculosis):a Delphi survey. Am Rev Respir Dis 1992;145: Abstract.
109. Anonymous. Management of persons exposed to multidrug resistant tuberculosis. MMWR Morb Mortal Wkly Rep 1992;41:61-71.
110. Interdepartmental Working Group on Tuberculosis. Recommendations for the control and prevention of tuberculosis at a local level. Department of Health and Welsh Office. June 1996, 30.